Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 15;19(12):1.
doi: 10.1007/s11864-018-0572-7.

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer


Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer

Katherine C Kurnit et al. Curr Treat Options Oncol. .


Use of poly(ADP-ribose) polymerase (PARP) inhibitors has greatly increased over the past 5 years. With several new Food and Drug Administration (FDA) approvals, three PARP inhibitors have entered into standard of care treatment for epithelial ovarian cancer (including ovarian, fallopian tube, and primary peritoneal cancer). Olaparib and rucaparib currently have indications for treatment of recurrent BRCA mutant ovarian cancer. Olaparib, rucaparib, and niraparib all have indications for maintenance therapy in recurrent platinum-sensitive ovarian cancer after response to platinum-based therapy. In our practice, we use both olaparib and rucaparib in the recurrent setting, and all three PARP inhibitors in the maintenance setting. Choice of which PARP inhibitor to use in either setting is largely based upon baseline laboratory values, number of prior therapies, and presence of a BRCA mutation and/or homologous recombination deficiency (HRD). As (HRD) and other biomarker assessments continue to improve, we anticipate being able to better identify which patients might most benefit from PARP inhibitor therapy in the future. The clinically available PARP inhibitors are currently undergoing extensive investigations in clinical trials. Other newer agents such as talazoparib, veliparib, 2X-121, and CEP-9722 are in earlier stages of development. As more FDA-approved indications for PARP inhibitor therapy in ovarian cancer become available, we anticipate the decision of which PARP inhibitor to use will become increasingly complex.

Keywords: Maintenance; Ovarian cancer; PARP inhibitors; Targeted therapy; Treatment.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles


    1. Ann Oncol. 2017 Mar 1;28(3):512-518 - PubMed
    1. J Clin Oncol. 2017 Jul 1;35(19):2193-2202 - PubMed
    1. Mutat Res. 2004 Mar;566(2):131-67 - PubMed
    1. Clin Cancer Res. 2017 Aug 1;23(15):4086-4094 - PubMed
    1. Gynecol Oncol. 2015 Jun;137(3):386-91 - PubMed

Publication types

MeSH terms